ArticleCanadian journal of gastroenterology = Journal canadien de gastroenterologie2011
Health care resource use and costs in Crohn's disease before and after infliximab therapy.
Article in Canadian journal of gastroenterology = Journal canadien de gastroenterologie, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Morbidity and treatment costs of cystic fibrosis in a middle-income country.Singapore medical journal · 2026Article
- Ideal Vial Size for Infliximab in the Treatment of Inflammatory Bowel Disease: An Analysis of Pharmaceutical Waste and Physician Opinions.Crohn's & colitis 360 · 2021Article
- Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany.Inflammatory intestinal diseases · 2021Article
- The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.Journal of the Canadian Association of Gastroenterology · 2019Article
- Evaluating the clinical and economic consequences of using video capsule endoscopy to monitor Crohn's disease.Clinical and experimental gastroenterology · 2019Article
- Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.United European gastroenterology journal · 2018Article
- Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective.International journal of clinical pharmacy · 2016Article
- Early surgery in Crohn's disease a benefit in selected cases.World journal of gastrointestinal surgery · 2016Article
- A UK cost of care model for inflammatory bowel disease.Frontline gastroenterology · 2015Article
- A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases.ClinicoEconomics and outcomes research : CEOR · 2014Review
- Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population.PeerJ · 2014Article
- Burden of Crohn's disease: economics and quality of life aspects in Italy.ClinicoEconomics and outcomes research : CEOR · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfliximab therapy in patients with Crohn's disease decreases resource use; however, the overall impact on health-related expenditures is unclear, especially beyond one year of study.
methodsA retrospective analysis of economic data one and two years before and after infliximab therapy was performed using patients who served as their own controls. Total health care resource use and direct health care costs were compared for patients with or without fistulae.
resultsPatients with one (n=66) and two (n=39) years of economic data before and after infliximab treatment had their resource use and direct health care costs estimated. In the year following initiation of infliximab therapy, there were significant decreases in health care use, reflected in total hospital days (495 to 155 [P<0.05]), inpatient colonoscopies (46 to 24 [P<0.05]), outpatient colonoscopies (58 to 33 [P<0.05]) and major surgeries (10 to 2 [P<0.05]). Direct health care costs of inpatient costs for luminal (-$1,747 [P<0.05]) and fistulizing disease (-$2,530 [P<0.05]), major surgeries (-$1240 [P<0.05]) and outpatient colonoscopies (-$184 [P<0.05]) were also significantly reduced before and after infliximab therapy. Total direct health care costs, including the drug cost of infliximab, increased ($21,416 [P<0.05]). In general, the trends in health care costs analyzed over four consecutive years paralleled the two consecutive-year analysis.
conclusionInfliximab therapy in patients with Crohn's disease resulted in a significant decrease in both resource use and health care costs, but an increase in total direct health care costs once the cost of infliximab was added.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.